[1] 唐超,张伯科,周琦,等.雷洛昔芬对蛋白尿慢性肾纤维化大鼠肾脏的保护作用[J].安徽医科大学学报,2010,45(3):363.
[2] 路会侠,李绍波.雷洛昔芬对去势大鼠骨密度IL-6的影响[J].海南医学,2008,19(6):111.
[3] 李勇,李善昌,宁尚波,等.柚皮甙复合自固化磷酸钙支架材料修复骨缺损的实验研究[J].口腔医学研究,2011,27(12):1039-1041.
[4] 苗波,隋长德,李慕勤,等.羟基磷灰石/骨碎补复合材料修复骨缺损的实验研究[J]黑龙江医药科学,2009,32(2):3-4.
[5] Parisien M,Silverberg SJ,Shane E,et al.The histomorphometry of bone in primary hyperparathyroidism: priservation of canellous bone structure.J Clin Endocrinol Metab.1999;70(4):930-938.
[6] 朱小峰,林李嵩,邱宇.雷洛昔芬对骨质疏松大鼠颅骨缺损修复的影响[J].河南河面外科,2010,16(6):39-44.
[7] Agrillo A,Sassano P,Mustazza MC,et al.Complex-type penertrating injuries of craniomaxillofacial region.J Craniofac Surg.2006;17(3):442-446.
[8] 贝朝涌,林卓峰,杨志,等.NGF对骨折愈合影响的研究[J].中国修复重建外科杂志,2009,23(5):570-576.
[9] Lawrence H,Bannister S,Martin M.Berry格式解破学[M].沈阳:辽宁教育出版社,1999:483-484.
[10] Silverberg SJ,Shane E,Cruz L,et al.Skeletal disease in primary hyperparathyoidism.J Bone Miner Res.2001;4:289-291.
[11] Matsumori H,Hattori K,Ohgushi H,et al.Raloxifene:its ossification-promoting effect on female mesenchymal stem cells.J Orthop Sci.2009;14(5):640-645.
[12] Parisien M,Cosman F,Mellish RW,et al.Bone structure in postmenopausal hyperparathyroid,osteoporotic,and normal women.J Bone Miner Res.2003;10:1393-1399.
[13] 邓慧鑫,关键,朱丽萍,张国梁,等.成骨细胞/CPC复合材料对兔下颌骨缺损的影响[J].黑龙江医疗科学,2010,33(3):919-921.
[14] 张滨,闫景龙,夏景君,等.骨形态发生蛋白在微小颗粒骨诱导成骨过程中的表达[J].中国矫形外科杂志,2004,12(16)12:48-49.
[15] Body JJ,Sternon J.Raloxifene (Celvista, Evista).Rev Med Brux.2000;21(1):35-41.
[16] Sato M,Bryant HU,Iversen P,et al.Advantages of raloxifene over alendronate or estrogen on nonreproductive tissues in the long-term dosing of ovariectomized rats.J Pharmacol Exp Ther.1996;279:298-305.
[17] Black LJ,Sato M,Rowley ER,et al.Raloxifene (LY139481HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.J Clin Invest.1994;93:63-66.
[18] Lane NE,Sanchez S,Modin GW,et al.Parathyroid hormone treament can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial.Clin Invest. 1998;102:1627-1633.
[19] Nakaoka D,Sugimoto T,Kobayashi T,et al.Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyoidism.Clin Edocrinol Metab.2000;85:1901-1907.
[20] Cosman F,Nieves J,Woelfert L,et al.Parathyroid hormone added to established hormone therapy:effects on vertebral fractrue and maintenance of bone mass after parathyroid hormone withdrawal.Bone Miner Res.2001;16:925-931.
[21] 毕崇萍,张绍芬,金慰芳.雷洛昔芬对大鼠成骨细胞的增殖、分化和矿化的影响[J].老年医学与保健,2007,13(4):223-222.
[22] Jordan VC.A currentview of tamoxifen for the treatment and prevention of breastcancer.Br J Pharmacol.1993;110(2): 507-517.
[23] Martino S,Costantion J,Mcnabb M,et al.The role of selective estrogen receptor modulators in the prevention of breast cancer:comparison of the clinical trials.Oncologist. 2004;9(2): 116-125.
[24] 姜荷艳,王锐,孙立军.雷洛昔芬对绝经后骨质疏松症的疗效观察[J].实用预防医学,2010,17(3):551-552.
[25] 王文波,陈中伟,陈统一.自固化磷酸钙人工骨的最新研究进展[J].生物医学工程杂志,2000,17(1):80-83.
[26] 曾中华,余黎,龚玲玲,等.骨折愈合过程中BMP-2和VEGF的表达[J].武汉大学学报:医学版,2005,26(4):467-469.
[27] Athanasopoulos AN,Schneider D,Keiper T,et al.Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activties in endothelial cells and promotes fracture healing.Biol Chem. 2007;282(37):26746-26753.
[28] Kaps C,Bramlage C,Smolian H,et al.Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destruction.Arthritis Rheum.2002;46(1):149-162.
[29] Yamaguchi A,Katagiri T,Ikeda T,et al.Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro.Cell Biol.1991;113(3):681-687.
[30] 张永刚,卢世璧,王继芳,等.骨形态发生蛋白和转化生长因子-β及碱性成纤维细胞生长因子在骨折修复中的表达[J].中华创伤杂志,2000,16(3):170-172.
[31] 郭书权,许建中.BMP-2诱导成骨及传送的研究进展[J].第三军医大学学报,2005,27(16):1707-1710.
[32] Yang L,Zhang KH,Zhu XF,et al.Effects of benefiting bone capsule on expression of bone morphogenetic protein-2 in bone tissue of theovariectomixed rats.Zhongguo Linchuang Kangfu.2006;10(3):190-192.
[33] Szczesny G. Growth factors in bone.Int Orthop.1998;22(6): 410-416.
[34] Chen D,Harris MA,Rossini G,et al.Bone morphoge-netic protein2(BMP-2)enhances BMP-3,BMP-4,and bone cell differentiation marker henes expression during the induction of mine ralizal bone mat rix formation in cultures of fetal rat calvarial osteoblasts.Calcif Tissue Int.1997;60(3):283-290.
[35] 胡德志,付刚.骨形态发生蛋白2(BMP-2)的研究进展[J].中医正骨,1998,10(1):47-49.
[36] Beck LS,Amento EP,Xu Y,et al.TGF-beta 1 induces bone closure of skull defects: temporal dynamics of bone formation in defects exposed to rhTGF-beta 1.J Bone Miner Res.1993;8:753.
[37] 卢翔,陈江宁,张峻峰.雷洛昔芬通过促进一氧化氮释放诱导脂肪干细胞向成骨细胞分化[J].中国药理学通报,2011,27(1):24.
[38] Tsuji K,Cox K,Bandyopadhyay A,et al.BMP4 is dispensable for skeletogenesis and fracture healing in the limb.J Bone Join Surg Am.2008;90(suppl.1):14.
[39] Sheehan JP,Sheehan JM,Sheehan JMH,et al.The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model.J Neursurg.2003;98(1):125-130.
[40] 杨济洲,徐林,穆岭.骨痛膏促进家兔骨愈合的实验研究[J].吉林中医药,2010,5(30):447-449. |